WATCHMAN FLX and New Blood Thinners Revolutionize Stroke Prevention

Results from the CHAMPION-AF global clinical trial indicate that the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) device is an effective first-line option for reducing stroke risk in patients with non-valvular atrial fibrillation (NVAF). Data presented on March 28, 2026, at the American College of Cardiology’s Annual Scientific Session & Expo showed the device worked as effectively as blood thinners in lowering the risk of stroke and death over a three-year period.

The study compared the WATCHMAN FLX device against non-vitamin K antagonist oral anticoagulants (NOACs), which are currently considered the leading contemporary blood thinners for stroke risk reduction in NVAF patients. According to the trial results, the WATCHMAN FLX device met all primary and secondary safety and efficacy endpoints.

One of the most significant findings from the CHAMPION-AF trial was that the WATCHMAN FLX device provided statistically superior protection from bleeding compared to the use of NOACs. These findings were published simultaneously with the ACC.26 presentation in The New England Journal of Medicine on March 28, 2026.

The Role of the Left Atrial Appendage in Stroke

Atrial fibrillation is a heart rhythm disorder affecting approximately 59 million people worldwide. This condition increases the risk of stroke by five times when compared to individuals with a normal heart rhythm.

In patients with non-valvular atrial fibrillation, more than 90% of heart-related blood clots form in the left atrial appendage (LAA). When these clots leave the LAA and travel to the brain, they can cause a stroke.

The WATCHMAN technology is designed to address this risk by permanently closing off the LAA. This is achieved through a single, minimally invasive procedure, offering a mechanical alternative to the lifelong use of anticoagulant medications.

Clinical Application and Patient Outcomes

For many patients, the prospect of avoiding long-term blood thinners is a primary motivator. Data from the device manufacturer indicates that in a clinical trial, 96% of people were able to stop their blood thinners 45 days after receiving the WATCHMAN implant.

More than 600,000 people have used the WATCHMAN implant to reduce their stroke risk and move away from blood thinner dependency. The device is currently the most implanted FDA-approved device proven to reduce stroke risk in people with atrial fibrillation not caused by a heart valve problem.

While the CHAMPION-AF trial positions the WATCHMAN FLX as a viable first-line therapy, the medical community continues to evaluate how these results should influence clinical practice. For example, Medscape has published an analysis titled Six Reasons Why CHAMPION-AF Should Not Change Practice, suggesting that the trial results may not immediately shift standard care protocols.

Comparing Mechanical Closure and Pharmacological Therapy

The choice between a mechanical closure device and NOACs involves weighing different risk profiles. While NOACs are effective at preventing clots, they carry a persistent risk of serious bleeding events.

The WATCHMAN FLX offers a one-time procedural intervention to eliminate the source of the clots. However, like all medical procedures, it carries its own set of risks. Patients are advised to consult with physicians to determine if they are candidates based on their specific medical history and risk factors.

The CHAMPION-AF trial provides a new evidence base for using the WATCHMAN FLX as an initial therapy rather than a secondary option for those who cannot tolerate blood thinners. By demonstrating similar efficacy to NOACs and superior safety regarding bleeding, the device presents a different pathway for long-term stroke prevention in the NVAF population.